Search results for "Losartan"

showing 10 items of 34 documents

Functional role of endothelial CXCL16/CXCR6-platelet-leucocyte axis in angiotensin II-associated metabolic disorders.

2018

Aims Angiotensin-II (Ang-II) is the main effector peptide of the renin-angiotensin system (RAS) and promotes leucocyte adhesion to the stimulated endothelium. Because RAS activation and Ang-II signalling are implicated in metabolic syndrome (MS) and abdominal aortic aneurysm (AAA), we investigated the effect of Ang-II on CXCL16 arterial expression, the underlying mechanisms, and the functional role of the CXCL16/CXCR6 axis in these cardiometabolic disorders. Methods and results Results from in vitro chamber assays revealed that CXCL16 neutralization significantly inhibited mononuclear leucocyte adhesion to arterial but not to venous endothelial cells. Flow cytometry and immunofluorescence s…

0301 basic medicineMaleRHOAPhysiologyMice Knockout ApoE030204 cardiovascular system & hematology0302 clinical medicineLeukocytesReceptorCells CulturedMetabolic SyndromebiologyChemistryAngiotensin IIMiddle AgedAortic AneurysmVascular endothelial growth factor ALosartanmedicine.anatomical_structurecardiovascular systemFemaleCardiology and Cardiovascular Medicinemedicine.drugSignal TransductionAdultBlood Plateletsmedicine.medical_specialtyEndothelium03 medical and health sciencesPhysiology (medical)Internal medicinemedicineCell AdhesionAnimalsHumansPlatelet activationReceptors CXCR6Angiotensin II receptor type 1Endothelial CellsChemokine CXCL16Platelet ActivationAngiotensin IICoculture TechniquesMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyCase-Control Studiesbiology.proteinAngiotensin II Type 1 Receptor BlockersCardiovascular research
researchProduct

Angiotensin II type II receptors and colonic dysmotility in 2,4-dinitrofluorobenzenesulfonic acid-induced colitis in rats

2016

Background: Angiotensin II (Ang II), the main peptide of the renin-angiotensin system (RAS), has been suggested to be involved in inflammatory bowel diseases. Since RAS has emerged as gut motility regulator, and dysmotility is associated with intestinal inflammation, our objective was to investigate in rat 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis the functionality of RAS and its contribution to colonic motor alterations. Methods: The effects of Ang II on the longitudinal colonic muscular contractility of control and DNBS-treated rats were characterized in vitro. Transcripts encoding for Ang II receptors were investigated by RT-PCR. Key Results: Inflamed preparations showed a l…

0301 basic medicineMalemedicine.medical_specialtyAngiotensin receptormedicine.drug_classColonPhysiologyInflammationAT2 receptorReceptor Angiotensin Type 2Bowel inflammationEndocrine and Autonomic SystemContractilityRenin-Angiotensin System03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsRats WistarReceptorAngiotensin II receptor type 1Endocrine and Autonomic SystemsChemistryAT1 receptorAngiotensin IIMuscle contractilityGastroenterologyMuscle SmoothNitric oxideReceptor antagonistColitisAngiotensin II030104 developmental biologyEndocrinologyLosartancardiovascular system030211 gastroenterology & hepatologyDinitrofluorobenzenemedicine.symptomGastrointestinal Motilityhormones hormone substitutes and hormone antagonistsmedicine.drugMuscle Contraction
researchProduct

Sexual dysfunction in hypertensive patients treated with losartan.

2001

ABSTRACT Background Impaired erectile function in men is a component of the dysmetabolic syndrome of high blood pressure as well as a sequela of antihypertensive therapy. This prospective interventional study in men with uncontrolled hypertension (blood pressure ≥ 140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan. Methods We evaluated the influence of a 12-week therapy with losartan in 82 hypertensive subjects with (n = 82) and without (n = 82) a diagnosis of erectile dysfunction using a self-administered questionnaire validated in another 60 subjects with hypertension. Results: From an initial sample of 323 hypertensive men and women,…

AdultMalemedicine.medical_specialtyAngiotensin-Converting Enzyme InhibitorsLosartanInternal medicinemedicineHumansProspective StudiesSexual Dysfunctions PsychologicalProspective cohort studyDiureticsAntihypertensive AgentsAgedbusiness.industrySequelaGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRegimenBlood pressureErectile dysfunctionLosartanSexual dysfunctionHypertensionFemalemedicine.symptombusinessSexual functionmedicine.drugThe American journal of the medical sciences
researchProduct

Effect of dual blockade of renin–angiotensin system on TGFβ1 and left ventricular structure and function in hypertensive patients

2007

The effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor beta1 (TGFbeta1), procollagen type I (PIP) and III (PIIIP), have been evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/ daily) and combined (losartan 50 mg/daily + ramipril 5 mg/daily) for 24 weeks. TGFbeta1, PIP and PIIIP, LVM, LVM/h(2.7) and other echo…

AdultMalemedicine.medical_specialtyLeft ventricular structureHeart VentriclesBlood PressureEnzyme-Linked Immunosorbent AssayAngiotensin II Receptor BlockersPeptide hormoneSeverity of Illness IndexDual blockadeCollagen Type ILosartanVentricular Function LeftRenin-Angiotensin SystemTransforming Growth Factor beta1Double-Blind MethodRamiprilInternal medicineRenin–angiotensin systemPrevalenceInternal MedicineHumansMedicineAntihypertensive AgentsUltrasonographyAnalysis of Variancebusiness.industryMiddle AgedAngiotensin IICollagen Type IIITreatment OutcomeEndocrinologyItalyHypertensionACE inhibitorDrug Therapy CombinationFemaleHypertrophy Left VentricularbusinessBiomarkersmedicine.drugJournal of Human Hypertension
researchProduct

Angiotensin II antagonists - an assessment of their acute toxicity.

2013

In Germany, increasing prescription rates of angiotensin II antagonists resulted in rising enquiries to Poisons Information Centres (PICs) during the last decade. Therefore, we aimed to assess their acute toxicity for deriving triage recommendations.An observational case series with data collected retrospectively from eight PICs in Austria, Germany and Switzerland. Inclusion criteria were monoexposure, defined dose, and documented follow-up.In total, 206 cases of exposures to angiotensin II antagonists were included (candesartan, 94; eprosartan, 3; irbesartan, 20; losartan, 26; olmesartan, 16; telmisartan, 18; and valsartan, 29). The median dose expressed as a multiple of their maximum dail…

AdultMalemedicine.medical_specialtyPoison Control CentersTime FactorsPharmacologyToxicologyIrbesartanInternal medicineGermanymedicineHumansAntihypertensive AgentsRetrospective Studiesbusiness.industryPoisoningEprosartanGeneral MedicineMiddle AgedAngiotensin IILosartanValsartanChild PreschoolMedian bodyFemaleTelmisartanDrug OverdoseHypotensionbusinessOlmesartanAngiotensin II Type 1 Receptor Blockersmedicine.drugClinical toxicology (Philadelphia, Pa.)
researchProduct

One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

2009

BACKGROUND AND OBJECTIVES: Hypertension is a significant cause of chronic renal injury and its effective treatment is capable of reducing the rate of renal failure. beta-Adrenoceptor antagonists (beta-blockers) have been reported to induce a deterioration in renal function, while several data have indicated a renoprotective effect of treatment with the angiotensin II type 1 receptor antagonist losartan. Previous studies of the interaction between the selective beta(1)-blocker bisoprolol and kidney function were performed only for short- and medium-term periods. The aim of this study was to compare the antihypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with th…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classRenal functionHemodynamicsEssential hypertensionKidneyKidney Function TestsLosartanlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineBisoprololHumansPharmacology (medical)Antihypertensive Agentshypertension losartanbisiprololbusiness.industryHeartGeneral MedicineMiddle AgedReceptor antagonistmedicine.diseaseAngiotensin IILosartanBisoprololHeart Function TestsHypertensionCardiologyFemalebusinessmedicine.drug
researchProduct

Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losarta…

2009

Abstract The incidence of cardiovascular diseases in premenopausal women is lower than in men or postmenopausal women. This study reports the discovery of a low grade of systemic inflammation, including monocyte adhesion to arterial endothelium, elicited by menopause or estrogen depletion. Chronic treatment with low dose of 17-β-estradiol or inhibition of the renin-angiotensin system reduced this inflammation. Using an in vitro flow chamber system with human arterial and venous endothelial cells, we found that leukocytes from healthy postmenopausal women were more adhesive to the arterial endothelium than those from premenopausal women regardless of the stimulus used on endothelial cells. I…

Adultmedicine.medical_specialtyEndotheliummedicine.drug_classOvariectomyImmunologyInflammationSystemic inflammationLosartanRats Sprague-DawleyInternal medicinemedicineCell AdhesionLeukocytesImmunology and AllergyAnimalsHumansCells CulturedInflammationCell adhesion moleculebusiness.industryEndothelial CellsEstrogensBenzazepinesMiddle Agedmedicine.diseaseRatsMenopausemedicine.anatomical_structureEndocrinologyLosartanEstrogenCase-Control StudiesOvariectomized ratFemaleEndothelium Vascularmedicine.symptomChemokinesMenopausebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion Moleculesmedicine.drugJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Aging modifies receptor expression but not muscular contractile response to angiotensin II in rat jejunum

2022

AbstractThe involvement of renin-angiotensin system in the modulation of gut motility and age-related changes in mRNA expression of angiotensin (Ang II) receptors (ATR) are well accepted. We aimed to characterize, in vitro, the contractile responses induced by Ang II, in jejunum from young (3–6 weeks old) and old rats (≥ 1 year old), to evaluate possible functional differences associated to changes in receptor expression. Mechanical responses to Ang II were examined in vitro as changes in isometric tension. ATR expression was assessed by qRT-PCR. Ang II induced a contractile effect, antagonized by losartan, AT1R antagonist, and increased by PD123319, AT2R antagonist, as well by neural block…

AgingJejunumPhysiologyAngiotensin IIAngiotensin II receptorsIntestinal motilityAnimalsGeneral MedicineReceptor Angiotensin Type 2BiochemistryReceptor Angiotensin Type 1LosartanRats
researchProduct

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.

2001

Background. The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Methods. This was a 6-month, open-label, prospective and multicentre study. A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study. After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (<140/90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of contr…

Blood Glucosemedicine.medical_specialtySystoleUrologyRenal functionBlood PressureType 2 diabetesLosartanDiabetic nephropathyDiastoleDiabetes mellitusInternal medicinemedicineAlbuminuriaHumansAntihypertensive AgentsGlycated HemoglobinTransplantationbusiness.industryBody Weightmedicine.diseaseAngiotensin IIUric AcidLosartanEndocrinologyBlood pressureHydrochlorothiazideDiabetes Mellitus Type 2NephrologyHypertensionRegression AnalysisMicroalbuminuriaDrug Therapy CombinationbusinessDiabetic Angiopathiesmedicine.drugNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Extent and duration of angiotensin ii antagonistic activity of irbesartan and candesartan cilexetil

2000

Clinical pharmacologybusiness.industryPharmacologyAngiotensin IIlaw.inventionCandesartanIrbesartanLosartanValsartanlawRenin–angiotensin systemInternal Medicinemedicinebusinessmedicine.drugAmerican Journal of Hypertension
researchProduct